Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Provectus Pharmaceuticals

We are pleased you are visiting our Provectus Pharmaceuticals Web site. As you will see, our company is engaged in exciting research & development activities. This site is intended to provide a useful introduction into the innovative world of Provectus.We are a group of dedicated and entrepreneurial scientists, working together for the past 10 years, engaged in developing breakthrough technologies for cancer and other serious diseases. Our primary goal at Provectus is to develop alternative treatments that are safer, more effective, less invasive and more economical than conventional therapies


Contact Details:
7327 Oak Ridge Hwy
Knoxville
Tennessee
37931
United States of America
Tel:+1 (865) 769-4011
Fax:+1 (865) 769-4013
Email:info@pvct.com
WWW:

www.pvct.com/




Loading...

Recent Publications by Provectus Pharmaceuticals:

Topical rose bengal: pre-clinical evaluation of pharmacokinetics and safety.
BACKGROUND AND OBJECTIVES: Rose bengal (RB) is a potent photosensitizer...
4th July, 2003
Provectus Pharmaceuticals, Inc., Knoxville, Tennessee 37931, USA. Lasers Surg Med. 2003;32(2):101-10.
DOI Direct Link

Press Releases on Provectus Pharmaceuticals:

BioPortfolio Logo
Video: Provectus Reports Encouraging Clinical Data at ASCO on Treatment of Metastatic Melanoma With PV-10 1st June, 2009 Provectus Pharmaceuticals
Objective Response of Treated Lesions Observed in 60% of Subjects KNOXVILLE, Tenn., June 1 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT), a development-stage
Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results 16th March, 2009 Provectus Pharmaceuticals
- Lead Investigator Professor John F. Thompson Presented Results at The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies in New York City - - Detailed Efficacy Data to be

BioNews Results for Provectus Pharmaceuticals:

NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
Freshnews.com:  Nov 20 2009 9:04PM Matching: provectus pharmaceuticals
NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
Centre Daily Times:  Nov 20 2009 8:49PM Matching: provectus pharmaceuticals
NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
Earthtimes.org:  Nov 20 2009 8:25PM Matching: provectus pharmaceuticals
NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
StockHouse USA:  Nov 20 2009 8:24PM Matching: provectus pharmaceuticals
NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
Earthtimes.org:  Nov 20 2009 8:23PM Matching: provectus pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution

View more Provectus Pharmaceuticals news.

Provectus Pharmaceuticals (PVCT.OB) Financial information Links from Barchart

PVCT.OB Quote from from Barchart.com
PVCT.OB Chart from from Barchart.com
PVCT.OB Profile from from Barchart.com
PVCT.OB Opinion from from Barchart.com

View more Provectus Pharmaceuticals finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 349 times since April 2007, the link to the organisation's website has been followed 54 times

Search for more companies in Knoxville

Search for more companies in Tennessee



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Provectus Pharmaceuticals

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.